AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, ...

Patients have been left frustrated and scared after learning that a life-saving breast cancer and endometriosis drug is to be ...

AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight ...

AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, ...

The approval relies on positive data from the POTOMAC Phase III trial.

AstraZeneca (AZN) climbed 3.1% as Bernstein reaffirms outperform rating, citing non-oncology portfolio as undervalued driver ...

At ASCO 2026, AstraZeneca unveiled initial clinical data for AZD-3470 in relapsed/refractory classical Hodgkin lymphoma.

AstraZeneca (LSE:AZN) received US FDA approval for IMFINZI (durvalumab) with BCG therapy in BCG naïve, high risk non muscle invasive bladder cancer, based on positive Phase III data showing a ...

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter AstraZeneca ( (GB:AZN)) has shared an update. AstraZeneca has confirmed that as of 31 ...

View AstraZeneca PLC AZN stock quote prices, financial information, real-time forecasts, and company news from CNN.

The U.K. drugmaker recently direct-listed its shares in the U.S., betting on a new-drug pipeline to achieve its revenue target by 2030.